

Asthma

A study to find out if a new medicine – MTPS9579A – works in people with asthma

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller

Trial Status Completed	Trial Runs In 5 Countries	Trial Identifier NCT04092582 2019-000795-41 GB41149
----------------------------------	-------------------------------------	--

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This clinical trial was done to study a new medicine called, MTPS9579A, for the treatment of asthma. This study investigated whether MTPS9579A was effective for controlling asthma in people who used inhaled corticosteroids (ICS) and another medicine – a second controller for the asthma. This was a Phase 2a, multicenter, randomized, placebo-controlled, double-blind study, conducted at 26 study centers in 5 countries.

Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland) Sponsor	Phase 2a Phase
--	--------------------------

NCT04092582 2019-000795-41 GB41149
Trial Identifiers

Eligibility Criteria:

Gender All	Age ≥18 Years & ≤ 75 Years	Healthy Volunteers No
----------------------	--------------------------------------	---------------------------------
